Article 22 Admissibility Review in Eight Days: What ANPP Checks

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Article 22 of Décret exécutif n° 20-324 gives the ANPP no more than 8 days for the admissibility review. The review covers three items: the completeness of the dossier, the authenticity of the documents, and whether the homologation fee has been paid. If the dossier is incomplete, the application is declared irrecevable and the applicant is notified.

GRZAN’s reading is blunt: these 8 days are the highest-leverage 8 days of the whole project. Everything prepared before submission determines whether the application enters technical evaluation at all, and everything done afterwards consists of responding to additional-information requests and waiting. An application that survives the admissibility review cleanly has already avoided the most common and most expensive failure mode in the Algerian procedure.

The practical consequence is that the admissibility review should be treated as a gate to be engineered, not a formality to be observed. The 22-item checklist of Article 4, the five-part format of Article 5 and the legalisation of foreign documents are all judged, in effect, within these 8 days.

2. Legal basis

  1. Décret exécutif n° 20-324 du 6 Rabie Ethani 1442 correspondant au 22 novembre 2020 relatif aux modalités d’homologation des dispositifs médicaux (Executive Decree No. 20-324 of 22 November 2020 on the procedures for the homologation of medical devices, JORADP No. 69, published 22 November 2020, pages 10–14, 46 articles): Article 22 (the 8-day admissibility review, its three subjects of review, and inadmissibility) and Article 21 (payment of the fee and issuance of the récépissé).
  2. Arrêté du 28 Ramadhan 1442 correspondant au 10 mai 2021 fixant la composition du dossier d’homologation et du dossier de renouvellement de la décision d’homologation des dispositifs médicaux à usage de la médecine humaine (Ministerial Order of 10 May 2021 fixing the composition of the homologation dossier and the renewal dossier for medical devices intended for human medicine, JORADP No. 55, published 14 July 2021, pages 21–24, 13 articles): Article 4 (22 items for the first application dossier), Article 5 (the five-part format) and Article 10 (21 items for the renewal dossier).
  3. Arrêté du 12 Dhou El Kaâda 1442 correspondant au 23 juin 2021 fixant les modalités d’homologation des dispositifs médicaux fabriqués localement et destinés exclusivement à l’exportation (Ministerial Order of 23 June 2021 on the homologation of locally manufactured medical devices intended exclusively for export, JORADP No. 62, published 15 August 2021, pages 23–25, 20 articles): Article 6 (the 8-day admissibility review, checking positioning and classification as well as completeness).

3. Expert insights

Insight 1: because authenticity is written into the review, the legalisation and translation chain must be finished before submission.

Among the three subjects of the Article 22 review, the authenticity of documents (l’authenticité des documents) follows completeness. Certificates issued abroad, such as the CLV, the CPP and ISO certificates, must complete legalisation and translation before they are filed, otherwise the application will be stopped at this gate. GRZAN’s standard practice is to schedule completion of legalisation and translation at least 1 month before the intended submission date, leaving margin for embassy queues and sworn-translation lead times.

Insight 2: inadmissibility is a restart, not a correction opportunity.

The wording of Article 22 is that an incomplete dossier is declared irrecevable and the applicant notified. Compare Article 9 of the Ministerial Order of 23 June 2021 on modification of the homologation decision, which uses the same term, irrecevable: this is a procedural rejection, not a one-time offer to fix defects. Once declared inadmissible, the applicant must resubmit, pay the fee again and let the deadlines start running again from the beginning.

Insight 3: the standard channel allows 8 days and the regularisation channel only 4, but the review standard is the same.

Article 7 of the Ministerial Order of 10 May 2021 on regularisation sets the admissibility review period at 4 days and states expressly that it is carried out in accordance with Article 22 of Executive Decree No. 20-324. In other words, the content of the review is identical and only the time is halved. A regularisation application therefore needs to be even better prepared, because there is less room to absorb any defect discovered at the front desk.

Insight 4: for export-only devices the review carries one extra subject, positioning.

Article 6 of the Ministerial Order of 23 June 2021 on export-only devices lists the admissibility review as checking the positioning and classification of the device, the completeness of the dossier, the authenticity of the documents, and payment of the homologation fee. The extra item, positioning, means confirming that the device really is locally manufactured and intended exclusively for export, which is precisely the condition that justifies the separate pathway.

4. Practical recommendations

  1. Before submission, run one complete check against the 22-item list of Article 4, with each item individually signed off.
  2. Complete legalisation and sworn translation of all documents issued abroad at least 1 month before submission.
  3. Assemble the dossier in the five-part format of Article 5, with numbering strictly following Annex II, to avoid format-related gaps.
  4. File the proof of fee payment with the dossier, request the récépissé on the spot and verify its date.
  5. On the regularisation channel, prepare to the 4-day standard; the shorter deadline never justifies lower completeness.
  6. For export-only devices, prepare the declaration that the device is intended exclusively for export, matching the positioning check.

5. Verification checklist

  • □ The pre-submission check against the 22-item list of Article 4 has been completed and signed.
  • □ Legalisation and translation of documents issued abroad have been completed.
  • □ The dossier has been assembled in the five-part format and numbering of Annex II.
  • □ The proof of fee payment has been filed with the dossier and the récépissé date verified.
  • □ The regularisation application has been prepared to the 4-day standard.
  • □ The export-only declaration has been prepared for export-only devices.

GRZAN helps manufacturers pass the Algerian admissibility review on the first attempt, with pre-submission completeness audits, legalisation and translation planning, and classification strategy aligned with Executive Decree No. 20-324 and the orders of 10 May and 23 June 2021. Whether your application follows the standard 8-day review or the 4-day regularisation track, GRZAN can structure the dossier to match what the ANPP actually checks. For support, contact GRZAN at info@grzanglobal.com.

Regulatory information verified as of 30 October 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail